The utility of cardiovascular drugs in the treatment of cerebrovascular disease

• Verfasst von: Bösel, Julian [VerfasserIn]
• Verfasst von: Amiri, Hemasse [VerfasserIn]
• Titel: The utility of cardiovascular drugs in the treatment of cerebrovascular disease
• Verf.angabe: Julian Bösel, Hemasse Amiri
• Jahr: 2010
• Umfang: 10 S.
• Fussnoten: Gesehen am 01.02.2023
• Titel Quelle: Enthalten in: Current opinion in investigational drugs
• Ort Quelle: London : Biomed Central, 2000
• Jahr Quelle: 2010
• Band/Heft Quelle: 11(2010), 9, Seite 1015-1024
• ISSN Quelle: 2040-3429
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Anti-Arrhythmia Agents
• Sach-SW: Anticoagulants
• Sach-SW: Antihypertensive Agents
• Sach-SW: Cardiovascular Agents
• Sach-SW: Cardiovascular Diseases
• Sach-SW: Cerebrovascular Disorders
• Sach-SW: Clinical Trials as Topic
• Sach-SW: Female
• Sach-SW: Humans
• Sach-SW: Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Sach-SW: Male
• Sach-SW: Platelet Aggregation Inhibitors
• Sach-SW: Risk Factors
• K10plus-PPN: 183293876X

Abstract

Cardiovascular and cerebrovascular diseases share many pathophysiological traits, often impact one another and share several risk factors, though not always to the same magnitude. Therefore, it is not surprising that many classes of cardiovascular drugs have demonstrated effectiveness in the primary prevention, acute treatment and secondary prevention of stroke. Important advances have been made since 2007 in the use of antiplatelets, anticoagulants, antihypertensives, antiarrhythmics and statins for the treatment of stroke. This review summarizes selected clinical trials of cardiovascular drugs completed from 2007 to 2010 that generated important evidence supporting the efficacy of these drugs in stroke treatment. Ongoing trials and preclinical research of promising agents and treatment strategies are also discussed.